COVID-19 binding assays enable rapid, high throughput, and in vitro screening of potential inhibitors of Spike-receptor complexes that facilitate SARS-CoV-2 viral entry. These enzyme-linked immunosorbent assays (ELISAs) use a 96-well plate and produce a colorimetric read-out for easy data interpretation. RayBiotech offers binding assays for studying interactions between the SARS-CoV-2 Spike protein (wild-type & variants) and key host cell receptors, including angiotensin I converting enzyme 2 (ACE2), neuropilin-1 (NRP1), and tyrosine-protein kinase receptor UFO (AXL). RayBio® COVID-19 binding assays are a perfect solution for laboratories with a limited budget. In addition, the kits can be handled safely at biosafety level 1 (BSL1), although the BSL requirements may change based on the sample type being tested. Spike-ACE2 inhibitors can also be screened in cell culture with our COVID-19 Pseudovirus Service.
Full testing service is available. E-mail [email protected] to learn more.
Multiple variants of the SARS-CoV-2 Spike protein compared to the wild-type "Wuhan" strain (Accession no. QHD43416) have emerged since the COVID-19 pandemic began. RayBiotech offers inhibitor screening ELISA kits with Spike variants that have mutations within the receptor binding domain (RBD). The binding of the RBD to ACE2 enables viral entry. Our Spike variant binding assays include:
B.1.1.7 Variant (U.K. Strain)
Spike protein mutations include a deletion at HV69-70 and two amino acid mutations: N501Y, D614G.
N501Y Variant (Common in U.K, Brazil & South Africa)
Spike protein with one amino acid mutation: N501Y.
E484K Variant (Common in Brazil & South Africa)
Spike protein with one amino acid mutation: E484K.
B.1.351 Variant (South Africa strain)
Spike protein with three amino acid mutations: K417N, E484K, N501Y.
P.1 Variant (Brazil strain)
Spike protein with three amino acid mutations: K417T, E484K, N501Y.
D614G Variant (U.K strain)
Spike protein with one amino acid mutation: D614G.